News
EQS-Adhoc: Eckert & Ziegler Plans Dividend of € 0.22 per Share for 2025
EQS-Adhoc: Eckert & Ziegler Plans Dividend of € 0.22 per Share for 2025
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
EQS-Adhoc: Formycon AG publishes preliminary figures for the 2025 fiscal year
EQS-Adhoc: Formycon AG publishes preliminary figures for the 2025 fiscal year
EQS-News: Immunic to Participate in Investor Conferences in March
EQS-News: Immunic to Participate in Investor Conferences in March
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
EQS-News: Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
EQS-News: Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
EQS-News: Eckert & Ziegler Enters Partnership with Molecular Partners to Support Development of Radio-DARPin Therapeutics
EQS-News: Eckert & Ziegler Enters Partnership with Molecular Partners to Support Development of Radio-DARPin Therapeutics
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
EQS-News: BRAIN Biotech announces 3M 25/26 results and breakthrough at BioIncubator company SolasCure: Aurase Wound Gel showing strong clinical evidence of superior debridement and healing in chronic wounds
EQS-News: BRAIN Biotech announces 3M 25/26 results and breakthrough at BioIncubator company SolasCure: Aurase Wound Gel showing strong clinical evidence of superior debridement and healing in chronic wounds
EQS-News: Formycon announces positive clinical data for Keytruda® biosimilar candidate FYB206 (pembrolizumab)
EQS-News: Formycon announces positive clinical data for Keytruda® biosimilar candidate FYB206 (pembrolizumab)
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Oxford Biomedica plc
Form 8.3 - The Vanguard Group, Inc.: Oxford Biomedica plc
EQS-News: Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
EQS-News: Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
EQS-Adhoc: BB Biotech AG publishes its 2025 annual report
EQS-Adhoc: BB Biotech AG publishes its 2025 annual report
EQS-News: Annual Report 2025: BB Biotech delivers strong performance and portfolio value realization
EQS-News: Annual Report 2025: BB Biotech delivers strong performance and portfolio value realization
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group PLC
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group PLC
EQS-News: Immunic Announces Closing of Oversubscribed Private Placement Financing
EQS-News: Immunic Announces Closing of Oversubscribed Private Placement Financing
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Oxford Biomedica plc
Form 8.3 - The Vanguard Group, Inc.: Oxford Biomedica plc